06:53 AM EST, 11/10/2026 (MT Newswires) -- The United States Patent and Trademark Office approved the intellectual property rights for Medivir's (MVIR.ST) fostroxacitabine bralpamide plus lenvatinib combination treatment for hepatocellular carcinoma and cancer metastases to the liver. The US regulator also granted a Patent Term Adjustment of 1,001 days to account for administrative delays during the application evaluation, extending the patent to at least January 2044 from April 2041, the pharmaceutical company said Tuesday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.